Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis
Condition: Osteomyelitis
MeSH terms: Osteomyelitis
Intervention: Dalbavancin; Standard of Care
Intervention description: Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.; Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.
Intervention MeSH terms: Dalbavancin
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 1.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Osteomyelitis; dalbavancin; antibiotic

Summary:

      This clinical study will be a multi-center, randomized, open-label, active-controlled,
      parallel-group study comparing dalbavancin to standard of care (SOC) therapy in
      osteomyelitis.
    

Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of osteomyelitis (first episode) defined by:

          -  Pain or point tenderness upon palpation or probing to bone

          -  Plain radiograph or Magnetic resonance imaging (MRI) consistent with osteomyelitis
             (indistinctly marginated edema-like pattern of bone marrow hypointensity on unenhanced
             T1-weighted sequences, hyperintensity on fat-saturated T2-weighted and Short tau
             inversion recovery (STIR) sequences and/or abnormal enhancement on gadolinium-enhanced
             fat-saturated T2-weighted sequences, with or without visible periostitis or cortical
             bone destruction) OR Gram-positive cocci documented on a baseline Gram-stain from a
             bone specimen

          -  Elevated C-reactive protein (CRP) (low sensitivity) above the upper limit of normal
             (ULN) (reference range for low sensitivity CRP is 3-10 mg/L)

          -  Subjects must be willing and able, if discharged from the hospital, to return to the
             hospital or a designated clinic for scheduled visits, treatment, laboratory tests, and
             other outpatient procedures as required by the protocol.

        Exclusion Criteria:

          -  Treatment with an investigational drug within 30 days preceding the first dose of
             investigational product.

          -  Receipt of > 24 hours of potentially effective IV antibacterial therapy for
             osteomyelitis within 96 hours of randomization, unless the pathogen isolated was
             documented to be Methicillin-resistant Staphylococcus aureus (MRSA) that was resistant
             to the administered antibiotic.

          -  A prior episode of osteomyelitis, or a failed course of therapy for osteomyelitis.

          -  Infection associated with a burn wound, with a sacral decubitus ulcer, or with
             multiple sites of osteomyelitis.

          -  Septic arthritis that is non-contiguous to osteomyelitis, as diagnosed by isolation of
             a pathogen from synovial fluid culture.

          -  Immunosuppression/immune deficiency

          -  Evidence of Gram-negative bacteria by Gram stain in the absence of Gram-positive
             organisms.

          -  Gram-negative bacteremia

          -  Patients with concomitant endocarditis, necrotizing fasciitis, or prosthetic material
             at the site of infection at the time of study initiation.

          -  Infection due to an organism known prior to study entry to not be susceptible to
             dalbavancin (dalbavancin mean inhibitory concentration [MIC] > 0.25 μg/mL) or
             vancomycin (vancomycin MIC > 2 μg/mL).

          -  Concomitant systemic antibacterial therapy for Gram-positive infections (eg, rifampin,
             gentamicin).

          -  Known or suspected hypersensitivity to glycopeptide antibiotics.

          -  Patients with a rapidly fatal illness, who are not expected to survive for 3 months.

          -  Pregnant or nursing females; positive urine (or serum) pregnancy test at Screening
             (pre-menopausal females only) or after admission (prior to dosing)

          -  Sexually active females of childbearing potential who are unwilling or unable to use
             an acceptable method of contraception from at least the first dose of study drug until
             the last pregnancy test.